D Allen Annis

5PUBLICATIONS
37CO-AUTHORS
Molecular targetsProteins and peptidesCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies.

|Jul 13, 2023
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.

Vincent Guerlavais, Tomi K Sawyer, Luis Carvajal

|Apr 28, 2023
Exploring new targets and chemical space with affinity selection-mass spectrometry.

Renaud Prudent, D Allen Annis, Peter J Dandliker

|Jul 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.

Mansoor N Saleh, Manish R Patel, Todd M Bauer

|Jul 07, 2021
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity.

Xiaolei Zhou, Madhurendra Singh, Gema Sanz Santos

Pageof 1

Frequent Collaborators

1 joint publications

Gema Sanz Santos

1 joint publications

Mariana M S Oliveira

1 joint publications

Lisa S Westerberg

1 joint publications

John Inge Johnsen